CR20180615A - Nuevos derivados de [1,2,3]triazol[4,5-d]pirimidina - Google Patents

Nuevos derivados de [1,2,3]triazol[4,5-d]pirimidina

Info

Publication number
CR20180615A
CR20180615A CR20180615A CR20180615A CR20180615A CR 20180615 A CR20180615 A CR 20180615A CR 20180615 A CR20180615 A CR 20180615A CR 20180615 A CR20180615 A CR 20180615A CR 20180615 A CR20180615 A CR 20180615A
Authority
CR
Costa Rica
Prior art keywords
triazol
pyrimidine
new derivatives
compound
formula
Prior art date
Application number
CR20180615A
Other languages
English (en)
Inventor
Uwe Grether
Mathias Valentin Westphal
Luca Gobbi
Rainer E Martin
Wolfgang Guba
Julian Kretz
Adriaan Pieter Ijzerman
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20180615A publication Critical patent/CR20180615A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)

Abstract

La invención se refiere a un compuesto de fórmula (I): en la que R1 a R4 y n son tal como se define en la descripción y en las reivindicaciones. El compuesto de fórmula (I) puede utilizarse como medicamento.
CR20180615A 2016-06-23 2017-06-20 Nuevos derivados de [1,2,3]triazol[4,5-d]pirimidina CR20180615A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16175924 2016-06-23
PCT/EP2017/064994 WO2017220517A1 (en) 2016-06-23 2017-06-20 [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor

Publications (1)

Publication Number Publication Date
CR20180615A true CR20180615A (es) 2019-03-05

Family

ID=56203225

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20180615A CR20180615A (es) 2016-06-23 2017-06-20 Nuevos derivados de [1,2,3]triazol[4,5-d]pirimidina
CR20220661A CR20220661A (es) 2016-06-23 2017-06-20 NUEVOS DERIVADOS DE [1,2,3]TRIAZOLO[4,5-D]PIRIMIDINA (Divisional 2018-0615)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20220661A CR20220661A (es) 2016-06-23 2017-06-20 NUEVOS DERIVADOS DE [1,2,3]TRIAZOLO[4,5-D]PIRIMIDINA (Divisional 2018-0615)

Country Status (24)

Country Link
US (1) US10457685B2 (es)
EP (2) EP4108665A1 (es)
JP (2) JP6962942B2 (es)
KR (2) KR20230062680A (es)
CN (4) CN115073476A (es)
AR (1) AR108845A1 (es)
AU (2) AU2017283136C1 (es)
BR (1) BR112018075143A2 (es)
CA (2) CA3206921A1 (es)
CL (1) CL2018003610A1 (es)
CO (1) CO2018011231A2 (es)
CR (2) CR20180615A (es)
IL (2) IL292015B2 (es)
MA (1) MA45442A (es)
MX (1) MX2018014684A (es)
MY (1) MY197244A (es)
PE (1) PE20190109A1 (es)
PH (1) PH12018502733B1 (es)
RU (1) RU2741597C2 (es)
SG (2) SG11201809678VA (es)
TW (2) TWI764908B (es)
UA (1) UA123834C2 (es)
WO (1) WO2017220517A1 (es)
ZA (1) ZA201807133B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311886B (zh) 2016-06-23 2021-11-09 豪夫迈·罗氏有限公司 [1,2,3]三唑并[4,5-d]嘧啶衍生物
WO2017220516A1 (en) 2016-06-23 2017-12-28 F. Hoffmann-La Roche Ag Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives
WO2017220544A1 (en) 2016-06-23 2017-12-28 F. Hoffmann-La Roche Ag Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives
EP4247799A1 (en) * 2020-11-23 2023-09-27 F. Hoffmann-La Roche AG New process for the manufacture of tetrazole derivatives
CN113387845B (zh) * 2021-07-16 2022-12-20 国药集团化学试剂有限公司 一种苯甲基磺酰氟的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60030303T2 (de) * 1999-10-18 2007-10-11 The University Of Connecticut, Farmington Cannabimimetische indolderivate
CA2587667A1 (en) * 2004-11-15 2006-05-18 Taisho Pharmaceutical Co., Ltd. Imine compound
US7776889B2 (en) 2005-03-31 2010-08-17 Schering Corporation Spirocyclic thrombin receptor antagonists
FR2887550A1 (fr) 2005-06-24 2006-12-29 Sanofi Aventis Sa Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique
ES2388881T3 (es) * 2006-03-30 2012-10-19 Irm Llc Azolopirimidinas como inhibidores de la actividad cannabinoide 1
US8629157B2 (en) * 2009-01-05 2014-01-14 Boehringer Ingelheim International Gmbh Pyrrolidine compounds which modulate the CB2 receptor
EP2311443A1 (en) 2009-10-15 2011-04-20 Rheinische Friedrich-Wilhelms-Universität Pharmaceutical composition containing cannabinoid-receptor 2 antagonists
CN102924457A (zh) * 2011-08-12 2013-02-13 上海恒瑞医药有限公司 三唑并嘧啶类衍生物、其制备方法及其用途
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
US9067943B2 (en) * 2011-11-25 2015-06-30 Hoffmann-La Roche Inc. [1,2,3]triazolo[4,5-D]pyrimidine derivatives
AU2014224784B2 (en) 2013-03-07 2018-03-08 F. Hoffmann-La Roche Ag Novel pyrazol derivatives
WO2014177527A1 (en) 2013-05-02 2014-11-06 F. Hoffmann-La Roche Ag Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
AU2014261585B2 (en) 2013-05-02 2018-03-08 F. Hoffmann-La Roche Ag Purine derivatives as CB2 receptor agonists
JP6441356B2 (ja) * 2013-09-06 2018-12-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規トリアゾロ［４，５−ｄ］ピリミジン誘導体
EP3215506B1 (en) 2014-11-07 2019-01-02 F.Hoffmann-La Roche Ag Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
CN109311886B (zh) 2016-06-23 2021-11-09 豪夫迈·罗氏有限公司 [1,2,3]三唑并[4,5-d]嘧啶衍生物
WO2017220516A1 (en) 2016-06-23 2017-12-28 F. Hoffmann-La Roche Ag Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives
WO2017220544A1 (en) 2016-06-23 2017-12-28 F. Hoffmann-La Roche Ag Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives

Also Published As

Publication number Publication date
JP2022009140A (ja) 2022-01-14
RU2741597C2 (ru) 2021-01-27
AU2017283136B2 (en) 2021-04-29
IL292015A (en) 2022-06-01
MY197244A (en) 2023-06-07
TW201811791A (zh) 2018-04-01
AU2017283136C1 (en) 2021-07-29
IL262711A (en) 2018-12-31
CR20220661A (es) 2023-02-21
IL292015B2 (en) 2024-07-01
TWI764908B (zh) 2022-05-21
KR20230062680A (ko) 2023-05-09
WO2017220517A1 (en) 2017-12-28
IL292015B1 (en) 2024-03-01
RU2018146657A3 (es) 2020-07-31
CN115093418A (zh) 2022-09-23
EP3475282A1 (en) 2019-05-01
CN113943297A (zh) 2022-01-18
BR112018075143A2 (pt) 2019-03-26
PH12018502733B1 (en) 2023-10-25
AR108845A1 (es) 2018-10-03
JP7308246B2 (ja) 2023-07-13
KR20190019085A (ko) 2019-02-26
AU2021206925B2 (en) 2023-03-30
MA45442A (fr) 2019-05-01
EP3475282C0 (en) 2023-08-09
AU2017283136A1 (en) 2018-11-15
ZA201807133B (en) 2019-09-25
MX2018014684A (es) 2019-02-28
CA3206921A1 (en) 2017-12-28
EP4108665A1 (en) 2022-12-28
AU2021206925A1 (en) 2021-08-19
CA3023043A1 (en) 2017-12-28
CL2018003610A1 (es) 2019-03-29
UA123834C2 (uk) 2021-06-09
TWI824380B (zh) 2023-12-01
CO2018011231A2 (es) 2019-02-08
RU2018146657A (ru) 2020-07-23
EP3475282B1 (en) 2023-08-09
CN109348716A (zh) 2019-02-15
CN115073476A (zh) 2022-09-20
IL262711B2 (en) 2023-07-01
IL262711B1 (en) 2023-03-01
JP6962942B2 (ja) 2021-11-05
KR102530131B1 (ko) 2023-05-10
PE20190109A1 (es) 2019-01-15
US10457685B2 (en) 2019-10-29
PH12018502733A1 (en) 2019-10-28
TW202216718A (zh) 2022-05-01
US20190127384A1 (en) 2019-05-02
SG10202113286RA (en) 2021-12-30
JP2019522648A (ja) 2019-08-15
SG11201809678VA (en) 2018-11-29

Similar Documents

Publication Publication Date Title
CR20160076A (es) NUEVOS DERIVADOS DE TRIAZOLO[4,5-d]PIRIMIDINA
CO2017005790A2 (es) Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas
CL2017001100A1 (es) Nuevas triazolo[4,5-d]pirimidinas
CR20160503A (es) Compuestos de [1,2,4] triazol e imidazol sustituidos, como fungicidas
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
CL2018000786A1 (es) Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
MX2017005769A (es) Derivados policiclicos activos como plaguicidas con sustituyentes que contienen azufre.
CR20150440A (es) Nuevos derivados de piridina
CR20150250A (es) Nuevos derivados de piridina
MX375099B (es) Derivados de aminotiazol útiles como agentes antivíricos.
UY33883A (es) Novedosos derivados heterocíclicos
CR20150447A (es) Nuevos derivados de pirazol
CL2018003610A1 (es) Nuevos derivados de [1,2,3]triazolo[4,5-d]pirimidina.
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
CR20170008A (es) Compuestos de [1,2,4] triazol e imidazol sustituidos
CR20160459A (es) Nuevos derivados de piridina
CR20150555A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina
CL2018001493A1 (es) Nuevos derivados de fenilo
CL2020001073A1 (es) Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
CR20160448A (es) Nuevos derivados de piridina
CR20150511A (es) Nuevos derivados de purina
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20180181A (es) Nuevos derivados de imidazol[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CO2018007756A2 (es) Nuevos derivados pirrolidina
CO7200259A2 (es) Nuevos derivados de piridina